UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.

UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.

Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated urinary tract infectionsPIVYA expected to be available in the U.S. in the 4th quarter of 2025.

Alembic buys UTI-focused Utility Therapeutics in USD 12 million deal

Vadodara: Alembic Pharmaceuticals Inc., a wholly owned subsidiary of Alembic Pharmaceuticals Limited, has acquired a 100 percent stake in Utility Therapeutics Ltd, a pharmaceutical company focused on...

Alembic acquires Utility Therapeutics for $12 million, strengthens US presence

Alembic Pharmaceuticals acquires Utility Therapeutics to launch Pivya for UTI treatment in the US market.

Alembic acquires Utility Therapeutics for USD 12 mn

Alembic acquires Utility Therapeutics for USD 12 mn

Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen U.S. footprint - Passionate In Marketing Alembic Pharmaceuticals Acquires Utility Therapeutics for $12 Million to Launch Pivya® in U.S.

3rd July, 2025, Bengaluru: Alembic Pharmaceuticals, Inc., the U.S. subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics Ltd. (“Utility”) in a $12 million deal to strengthen its presence in the U.S. market. Alembic will begin the commercialization of Utility’s recently FDA approved product Pivya® (pivmethecillam) for the treatment of uncomplicated urinary tract infections. Pivya® […] The post Alembic Pharmaceuticals acqui…

Alembic Pharmaceuticals gains as its arm set to acquire Utility Therapeutics

Alembic Pharmaceuticals is currently trading at Rs 1000.60, up by 10.95 points or 1.11% from its previous closing of Rs 989.65 on the BSE. The scrip opened at Rs 999.05 and has touched a high and low of Rs 1010.00 and Rs 980.00 respectively. So far 20842 shares were traded on the counter. The BSE group ‘A’ stock of face value Rs 2 has touched a 52-week high of Rs 1296.15 on 09-Oct-2024 and a 52-week low of Rs 725.60 on 03-Mar-2025. Last one week…